Examining the Future of Molecular Imaging

February 9, 2009 CPDC

HAMILTON: FEBRUARY 9, 2009 – The future of molecular imaging and its impact on patient care highlighted the CPDC’s inaugural probe development workshop on January 30.

More than 120 participants, spanning multiple sectors – academia, health care, not-for-profit, federal/provincial government and industry – gathered at the University Club on McMaster University’s campus in Hamilton, Ontario. Workshop attendees learned about the latest innovations in molecular imaging and associated technologies from leaders in the field.

Featured speakers included:

Jason S. Lewis, PhD, chief of Radiochemistry and associate vice chair of Basic Research at Memorial Hospital for Cancer and Allied Diseases, as well as an associate member within Memorial Sloan-Kettering Cancer Center.
John Joyal, PhD, vice president of Discovery Research at Molecular Insight Pharmaceuticals in Cambridge, MA
Brian Warrington, PhD, former vice president of Technology Development at GlaxoSmithKline in the United Kingdom
Raymond Gibson, PhD, former senior investigator at Merck Research Laboratories in Philadelphia, PA

CPDC Scientific Director and CEO John Valliant presented an overview of the Centre and the scope of services provided. He also opened the CPDC’s inaugural Call for Proposals where applicants from Canadian not-for-profit research institutions with expertise in molecular probe development are eligible for project awards.


For more information, please contact:

T: 905-525-9140, ext 21212
E: info@imagingprobes.ca

More news from CPDC

Centre for Probe Development and Commercialization (CPDC) Appoints New Head of Business Development

Hamilton, Ontario, November 16, 2018 – The Centre for Probe Development and Commercialization (CPDC) is proud to introduce the new Head of Business Development, Bruno Paquin, PhD. Bruno comes to us with years of experience in research and development and he brings with him extensive knowledge of scientific operations in life and health sciences, as

Centre for Probe Development & Commercialization (CPDC) Appoints New CEO and President

Hamilton, Ontario, October 3, 2018 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, today is announcing that its founder, Dr. John Valliant, has stepped down from his role as CEO to focus his time as the CEO of Fusion Pharmaceuticals. Dr. Valliant will

CPDC and McMaster Nuclear Reactor Sign Research Agreement for Production of High Value Medical Isotopes

HAMILTON, Ontario, September 13, 2018 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, and the McMaster Nuclear Reactor facility (MNR), a leading research reactor program that provides a source of medical radioisotopes, announced today that they have signed an agreement to explore the

For more information contact us at: